I have written about two diet drugs in recent years
[4] Long-acting GLP-1 receptor agonists offer less frequent dosing and include: Dulaglutide (Trulicity) : Once-weekly injection, available in single-dose pens ranging from 0.75 mg to 4.5 mg Semaglutide (Ozempic, Wegovy) : Once-weekly injection
Drugging this type of GPCR with small molecules has its challenges say Jeff Finer, chief executive of Septerna, a biotech based in south San Francisco, US
"While gastrointestinal side effects like nausea and constipation are common, they are usually temporary and manageable." Dr
Aoi W, Ogaya Y, Takami M, Konishi T, Sauchi Y, Park EY, et al
For patients with an A1C of 6.5% to 7.5%, metformin is the preferred initial agent, with GLP-1 receptor agonists, dipeptidyl-peptidase-4 (DPP-4) inhibitors, thiazolidinediones (TZDs), or an alpha-glucosidase inhibitor listed as viable alternatives